---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-052083"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:34:42.521920+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Senti Bio Q3 net loss $18.1M; cash $12.2M; ASH data ahead

## Summary
- Cash and cash equivalents $12.2M as of Sep 30, 2025, down from $48.3M at Dec 31, 2024.
- Net loss $18.1M ($0.69 per share) for Q3 2025; R&D expense $10.5M, G&A $6.4M.
- Phase 1 SENTI-202 in AML: updated clinical data to be presented at ASH meeting Dec 6-9, 2025.
- Abstracts accepted for oral and poster presentations at ASH; company will host webcast.
- No revenue; pre-commercial biotech focused on gene circuit platform for cell therapy.

## SEC filing metadata
- accession: 0001628280-25-052083
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000162828025052083/0001628280-25-052083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000162828025052083/snti-20251113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-052083
- JSON: https://secwatch.observer/filing/0001628280-25-052083.json
- Plain text: https://secwatch.observer/filing/0001628280-25-052083.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.